VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Large Decrease in Short Interest

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totaling 482,674 shares, a drop of 18.2% from the November 30th total of 590,135 shares. Based on an average daily trading volume, of 825,976 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.5% of the shares of the stock are sold short. Currently, 1.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 825,976 shares, the days-to-cover ratio is currently 0.6 days.

VYNE Therapeutics Stock Down 0.5%

VYNE opened at $0.56 on Wednesday. VYNE Therapeutics has a 52-week low of $0.28 and a 52-week high of $4.30. The firm’s 50 day moving average is $0.41 and its 200-day moving average is $0.58. The firm has a market capitalization of $18.64 million, a P/E ratio of -0.72 and a beta of 1.99.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. VYNE Therapeutics had a negative return on equity of 80.84% and a negative net margin of 6,425.19%.The business had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.13 million. Equities analysts expect that VYNE Therapeutics will post -0.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of VYNE Therapeutics to a “sell” rating in a research report on Saturday, December 20th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $4.50.

Hedge Funds Weigh In On VYNE Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. ADAR1 Capital Management LLC acquired a new stake in VYNE Therapeutics during the first quarter valued at approximately $111,000. Adage Capital Partners GP L.L.C. raised its stake in VYNE Therapeutics by 123.3% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 344,134 shares of the company’s stock valued at $544,000 after purchasing an additional 190,000 shares during the period. Parkman Healthcare Partners LLC boosted its position in shares of VYNE Therapeutics by 42.5% in the first quarter. Parkman Healthcare Partners LLC now owns 217,978 shares of the company’s stock worth $344,000 after buying an additional 65,005 shares during the period. Exome Asset Management LLC grew its holdings in shares of VYNE Therapeutics by 30.9% during the first quarter. Exome Asset Management LLC now owns 462,801 shares of the company’s stock valued at $731,000 after buying an additional 109,367 shares in the last quarter. Finally, Acorn Capital Advisors LLC lifted its stake in VYNE Therapeutics by 72.0% in the 1st quarter. Acorn Capital Advisors LLC now owns 785,938 shares of the company’s stock worth $1,242,000 after acquiring an additional 328,968 shares in the last quarter. 83.78% of the stock is currently owned by institutional investors and hedge funds.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.